Polymorphisms in immune function genes and non-Hodgkin lymphoma survival

Journal of Cancer Survivorship

Volumn 6, Issue 1, 2012, Pages 102-114

  Aschebrook Kilfoy, Briseis ^a,b   Zheng, Tongzhang ^a   Foss, Francine ^c   Ma, Shuangge ^a   Han, Xuesong ^a   Lan, Qing ^b   Holford, Theodore ^a   Chen, Yingtai ^d   Leaderer, Brian ^a   Rothman, Nathaniel ^b   Zhang, Yawei ^a  

^a YALE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CANCER HOSPITAL   (China)

Author keywords

Cytokines; Non Hodgkin lymphoma; Single nucleotide polymorphisms; Survival

Indexed keywords

CYTOKINE;

ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIOECONOMICS; SURVIVAL; SURVIVOR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONNECTICUT; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; SURVIVORS; YOUNG ADULT;

EID: 84857138402     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-010-0164-4     Document Type: Article

References (29)

1. Clarke C, O'Malley C. Chapter 28 Non-Hodgkin lymphoma. In: Ries LAG, Yong JL, Keel GE, Eisner MP, Lin YD, Horner M-JD [eds] Cancer survival among adults: U. S. SEER Program, 1988-2001, patient and tumor characteristics. National Cancer Institutes, SEER Program, NIH, Bethsda, pp 235-242, 2007.
2. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control. 2008; 19(8): 841-58. Epub 2008 Mar 26.
3. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000; 92(15): 1240-51.
4. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987-94.
5. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001; 357: 539-45.
6. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002; 94(7): 2015-23.
7. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006; 107: 4101-8.
8. Morton LM, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang Y, et al. Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. Br J Cancer. 2003; 89(11): 2087-92.
9. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004; 15(4): 419-28.
10. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 3835-49.
12. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006; 34: D617-21.
13. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004; 74: 106-20.
14. Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, et al. Expression of an exogenous interleukin-6 gene in human Epstein Barr virus B-cells confers growth advantage and tumorigenicity. J Exp Med. 1990; 172: 61-8.
15. Smallwood L, Allcock R, van Bockxmeer F, Warrington N, Palmer LJ, Iacopetta B, et al. Polymorphisms of the interleukin-6 gene promoter and abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2008; 35(1): 31-6. Epub 2007 Nov 8.
16. Yee C-Y, Biondi A, Wang X-H, Iscove NN, de Sousa J, Aarden LA, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989; 74: 798-804.
17. Takeshita M, Sumiyoshi Y, Masuda Y, Ohshima K, Yoshida T, Kikuchi M, et al. Cytokine[interleukin- la, interleukin- Ip, tumor necrosis factor a, andinterleukin-6]-possessing cells in lymph nodes of malignant lymphoma. Pathol Res Pract. 1993; 189: 18-25.
18. Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, et al. Interleukin 6 gene expression in normal and neoplastic B-cells. J Clin Invest. 1989; 83: 1512-8.
19. Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, et al. Interleukin-6 production in high-grade B-lymphomas: correlation with the presence of malignant imniunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood. 1992; 80: 498-504.
20. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin 6. a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest. 1989; 84: 008-11.
21. Chopra GS, Chitalkar PG, Jaiprakash MP. Cytokines: as useful prognostic marker in lymphoma cases. MJAFI. 2004; 60: 45e49.
22. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007; 109(12): 5439-46. Epub 2007 Feb 27.
23. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994; 29: 423-9.
24. Kitadai Y, Haruma K, Sumii K, et al. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol. 1998; 152: 93-100.
25. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol. 1999; 189: 546-51.
26. Molica S, Vitelli G, Levato D, Levato L, Dattilo A, Gandolfo GM. Clinicobiological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia. Haematologica. 1999; 84: 208-11.
27. SEER Limited-Use 1973-2004-ASCII Text Data: Surveillance, Epidemiology, and End Results [SEER] Program [www. seer. cancer. gov] Limited-Use Data [1973-2004], National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
28. Kuppers R. Prognosis in follicular lymphoma-it's in the microenvironment. N Engl J Med. 2004; 351: 2152-3.
29. Hunter KW, Crawford NP. Germ line polymorphism in metastatic progression. Cancer Res. 2006; 66: 1251-4.